Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.
October 4, 2022
Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego’s lead candidate, PTG-630, against Alzheimer’s disease (AD).
September 30, 2021
Praetego wins Innovator’s Pitch Challenge at RESI Longevity
June 1, 2021
Praetego Inc, a preclinical stage pharmaceutical company developing novel candidates against chronic diseases of aging, is pleased to announce an award of a $458K grant to study the Amadorin candidates for the treatment of Alzheimer’s Disease.
